Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05994209 · ClinicalTrials.gov registry record · Phase 1

Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors

A Phase 1 study of Nicotine Use Disorder and Nicotine Vaping, sponsored by Washington University School of Medicine.

Recruiting
Registry status
Phase 1
Development phase
189
Enrollment target
1
Study location

NCT05994209: Recruiting Phase 1 study of Nicotine Use Disorder and Nicotine Vaping, sponsored by Washington University School of Medicine.

NCT05994209 is a Phase 1 study of Nicotine Use Disorder and Nicotine Vaping that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 189 participants, above the 76-participant average among 7 other Nicotine Use Disorder trials with a reported enrollment target (149% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05994209, a Phase 1 study of Nicotine Use Disorder and Nicotine Vaping, is actively recruiting participants, sponsored by Washington University School of Medicine.

RECRUITING
Registry status
Phase 1
Development phase
189 participants
Enrollment target
1
Study location

Study Summary

Use of vaping products (e.g., electronic nicotine delivery systems, e-cigarettes) has been increasing rapidly, particularly among teens and young adults. With limited information on the long-term effects of vaping products, health information about vaping has been somewhat unclear in regards to associated health risks. Teens and young adults may be reluctant to disclose their use of vaping products to parents or health providers and instead turn to social media to share and seek out information regarding vaping risks and cessation supports. Thus, our current proposal outlines the use of social media to identify teens and young adults socially networking about vaping, the use of an online chatbot screen to evaluate individual cessation support needs, and the use of a digital intervention system to support vaping cessation. The mobile intervention used in this study is based on a widely-used evidence-based mobile intervention for combustible smoking (i.e., quitSTART) and has been adapted for vaping and young adults to include an in-app chatbot to guide users to tailored content and to motivate and encourage their cessation efforts. We aim to integrate our social media recruitment and online screening approach to connect individuals with this mobile app intervention, and will conduct a randomized controlled trial to evaluate user engagement with and preliminary efficacy of the digital intervention on reducing vaping behaviors among teens and young adults.

Primary Outcome

Vaping cessation as assessed by 7 day self-reported vaping abstinence at follow-up. Timeline follow back procedures will be used to establish abstinence or if participants lapsed (their first instance of vaping post quit) or relapsed (vaped on 7 consecutive days) at each follow up time point.

Interventions

  • DEVICE quitSTART Mobile Application
  • BEHAVIORAL Chatbot Feature in quitSTART Mobile Application

Study Locations (1)

Missouri

  • Washington University in St. Louis, School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 189 participants
Start Date 2025-06-04
Est. Completion 2026-06
Phase Phase 1

What NCT05994209 shows while recruiting

NCT05994209 is an interventional study that assigns participants to a tested intervention. The registered 189 participants enrollment target is mid-sized for trials with a published cap, above the 76-participant average among 7 other Nicotine Use Disorder trials with a reported enrollment target (149% higher).

The record links to 2 conditions, with Nicotine Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which quitSTART Mobile Application is the first listed.

NCT05994209 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT05994209 about?

NCT05994209 is a clinical study titled "Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors". Use of vaping products (e.g., electronic nicotine delivery systems, e-cigarettes) has been increasing rapidly, particularly among teens and young adults. With limited information on the long-term effects of vaping products, health information about vaping has been somewhat unclear in regards to asso...

What is the current status of trial NCT05994209?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 189 participants. The study started on 2025-06-04. Estimated completion is 2026-06.

What conditions does trial NCT05994209 study?

This clinical trial studies the following conditions: Nicotine Use Disorder, Nicotine Vaping.

What interventions are being tested in trial NCT05994209?

The interventions under investigation include: quitSTART Mobile Application (DEVICE), Chatbot Feature in quitSTART Mobile Application (BEHAVIORAL).

Who is sponsoring clinical trial NCT05994209?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05994209 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Nicotine Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02734537 · 189 participants · Phase 2

    Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

  • NCT05058651 · 189 participants · Phase 2

    Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

  • NCT05673408 · 189 participants

    NIBP Validation Study

  • NCT06567795 · 189 participants

    PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05994209, the US trial registry maintained by the National Library of Medicine. NCT05994209 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.